| 07/29/21 |
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders |
| 07/29/21 |
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022 |
| 07/16/21 |
CytRx Corporation Announces Closing of $10 Million
Offering To Healthcare-Focused Institutional Investor |
| 07/13/21 |
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor |
| 06/30/21 |
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C |
| 06/18/21 |
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C |
| 06/02/21 |
CytRx to Present at Upcoming Investor Conferences |
| 05/13/21 |
CytRx Comments on Quarterly Results and Year-to-Date Progress |
| 05/07/21 |
CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis |
| 04/01/21 |
CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis |
| 03/25/21 |
CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress |
| 03/08/21 |
CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C |
| 03/04/21 |
CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C |
| 03/03/21 |
CytRx to Participate in Upcoming Investor Conferences |
| 02/11/21 |
CytRx is Added to the LD Micro Index |
| 12/31/20 |
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C |
| 12/22/20 |
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest |
| 12/07/20 |
CytRx Announces Orphazyme’s U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C |
| 11/16/20 |
CytRx Comments on Quarterly Results and Recent Strategic Progress |
| 11/11/20 |
CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C |
| 10/27/20 |
CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol |
| 10/13/20 |
CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment |
| 10/07/20 |
CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer |
| 09/30/20 |
CytRx Issues Statement Regarding Orphazyme’s Global Offering |
| 09/17/20 |
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C |
| 09/03/20 |
CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation |
| 08/24/20 |
CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities |
| 08/13/20 |
CytRx’s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign |
| 08/10/20 |
CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders |
| 07/21/20 |
CytRx Corporation Highlights Orphazyme’s Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C |
| 07/20/20 |
CytRx Corporation Highlights Orphazyme’s Announcement of its Collaboration with The Michael J. Fox Foundation on Parkinson’s Disease Research |
| 06/29/20 |
CytRx Corporation Highlights Orphazyme’s Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease |
| 06/01/20 |
CytRx Corporation Highlights Orphazyme’s Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C |
| 05/26/20 |
CytRx Corporation Highlights Orphazyme’s Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS) |
| 05/21/20 |
CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin |
| 04/29/20 |
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease |
| 03/10/20 |
CytRx Corporation Provides Update on Management Change |
| 02/28/20 |
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S |
| 02/11/20 |
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM) |
| 02/04/20 |
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S |
| 01/29/20 |
CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin |
| 12/19/19 |
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin |
| 08/09/19 |
CytRx Corporation Reports Second Quarter 2019 Financial Results |
| 07/30/19 |
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C |
| 07/22/19 |
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis |
| 06/27/19 |
CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com |
| 06/26/19 |
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation |
| 06/19/19 |
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C |
| 05/31/19 |
CytRx Corporation to Commence Trading on OTCQB Venture Market |
| 05/15/19 |
CytRx Corporation Reports First Quarter 2019 Financial Results |
| 05/08/19 |
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer |
| 05/02/19 |
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S |
| 04/29/19 |
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S |
| 03/29/19 |
CytRx Corporation Reports 2018 Financial Results |
| 03/12/19 |
CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems |
| 02/13/19 |
CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor |
| 02/11/19 |
CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy |
| 02/06/19 |
CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S |
| 01/14/19 |
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial |
| 12/21/18 |
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic |
| 11/28/18 |
CytRx Corporation to Present at the 11th Annual LD Micro Main Event |
| 11/08/18 |
CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting |
| 11/02/18 |
CytRx Corporation Reports Third Quarter 2018 Financial Results |
| 10/31/18 |
Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline |
| 10/29/18 |
CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018 |
| 09/25/18 |
CytRx Corporation to Present at the 2018 MicroCap Conference |
| 09/13/18 |
CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S |
| 08/27/18 |
CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018 |
| 08/06/18 |
CytRx Corporation Reports Second Quarter 2018 Financial Results |
| 08/01/18 |
CytRx Corporation Pays Off Balance of Outstanding Debt |
| 07/30/18 |
CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018 |
| 07/25/18 |
CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application |
| 07/23/18 |
CytRx Corporation Announces Expiration of Outstanding Warrants |
| 07/16/18 |
CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference |
| 06/28/18 |
CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial |
| 06/25/18 |
CytRx Corporation Joins Russell Microcap® Index |
| 06/21/18 |
CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology |
| 06/07/18 |
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting |
| 06/04/18 |
CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates |
| 05/30/18 |
CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference |
| 05/17/18 |
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting |
| 05/15/18 |
CytRx Announces Closing of $7.0 Million Registered Direct Offering |
| 05/11/18 |
CytRx Announces $7.0 Million Registered Direct Offering |
| 05/08/18 |
CytRx Reports First Quarter 2018 Financial Results |
| 05/07/18 |
CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018 |
| 05/03/18 |
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer |
| 04/30/18 |
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting |
| 04/18/18 |
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting |
| 04/09/18 |
CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference |
| 03/19/18 |
CytRx Reports 2017 Financial Results |
| 03/16/18 |
CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference |
| 03/15/18 |
CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials |
| 03/12/18 |
CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018 |
| 03/05/18 |
CytRx to Present at the 30th Annual ROTH Conference |
| 03/01/18 |
CytRx Announces Key Addition to Corporate Development Team |
| 02/28/18 |
CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates |
| 02/22/18 |
CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting |
| 02/06/18 |
CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference |
| 02/05/18 |
CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma |
| 01/17/18 |
CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer |
| 01/03/18 |
CytRx Corporation to Present at Biotech Showcase 2018 |
